[TRH and T3 suppression tests after 131I therapy of thyrotoxicosis (author's transl)]. 1976

H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu

TRH and T3 suppression tests were performed on patients (124 cases) with Graves' disease who underwent radiation therapy. TRH test was performed at 4-6 months (Group I), 6-12 months (Group II), 12-24 months (Group III) and 24-50 months (Group IV) after final radiation therapy, and T3 suppression test was performed just after each TRH test. The response to TRH test was defined as positive when the basal TSH value was less than 2.0 muU/ml and the peak value was more than 6.2 muU/ml following TRH (500 mug) injection. T3 suppression test was performed by measuring the 24-hr thyroidal uptake of radioiodine after daily administration of 75 mug of T3 for 8 days. The response was defined as positive when the value for 24-hr uptake after T3 administration was less than half of the control value. The results were as follows; 1) Among 124 patients in Group I to IV who were clinically euthyroid and whose T3-RU and T4 values were normal, compared with other groups, Group IV (2-4.2Y) showed a significantly higher percentage of positive responses to both TRH and T3 suppression tests. However, among 49 of 124 patients whose T3 was also normal, there were no significant differences between the groups. 2) The value of triiodothyronine was above the normal range in many cases up to 2 years after radiation therapy (in Group I, II, III). 3) There were no significant differences in the percentage of hyperresponses between any of the four groups. Half of the patients who showed positive responses to TRH test showed exaggerated responses. 4) In all cases when the responses to TRH and T3 suppression tests changed from negative to positive, thyroxine and triiodothyronine concentrations must be within the normal range. In particular, the major determinant seems to be the value of triiodothyronine. 5) As in more than 30% of cases TRH and T3 supression tests changed from negative to positive, thyroxine and triiodothyronine concentrations must be within the normal range. In particular, the major determinant seems to be the value of triiodothyronine. 5) As in more than 30% of cases TRH and T3 suppression tests remained negative even though their T3-RU, T4, T3, values became normal after radiation therapy, the regulation of hypothalamo-hypophyseal thyroid axis do not always return to normal even though circulating thyroidal hormone level return to an euthyroid state.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013972 Thyrotropin A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. Thyroid-Stimulating Hormone,TSH (Thyroid Stimulating Hormone),Thyreotropin,Thyrotrophin,Hormone, Thyroid-Stimulating,Thyroid Stimulating Hormone

Related Publications

H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
December 1975, Nihon Naibunpi Gakkai zasshi,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
January 1978, Nihon Naibunpi Gakkai zasshi,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
January 1981, Nihon Naibunpi Gakkai zasshi,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
January 1980, La Nouvelle presse medicale,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
June 1974, Deutsche medizinische Wochenschrift (1946),
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
July 1977, Monatsschrift fur Kinderheilkunde,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
May 1999, Nuclear medicine communications,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
February 1974, Nihon Naibunpi Gakkai zasshi,
H Tamai, and T Tsushimi, and K Shizume, and K Kuma, and H Suematsu
December 1987, Zhonghua yi xue za zhi,
Copied contents to your clipboard!